 LEXINGTON, Mass., March 05, 2021 GLOBE NEWSWIRE -- Keros Therapeutics, Inc. Keros or the Company Nasdaq: KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from preclinical studies of KER-050 and the Companys ALK2 inhibitor program at the virtual European School of Haematology ESH 2nd Translational Research E-Conference held March 5 through 7, 2021. 